Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

FDA approves oral semaglutide for reducing cardiovascular risks in adults with type 2 diabetes
Rybelsus from Novo Nordisk is officially the first oral GLP-1 drug approved for this indication. The FDA's decision was based on the SOUL trial, which included data from more than 9,000 patients with type 2 diabetes.
Hypertrophic Cardiomyopathy Association supports study of potential treatment for nonbstructive HCM
No medications are currently approved for the treatment of nonobstructive hypertrophic cardiomyopathy. Could a new drug from Imbria Pharmaceuticals be the first?
SGLT2 inhibitors after TAVR may boost survival, limit bioprosthetic valve dysfunction
Prescribing these drugs to TAVR patients could improve certain clinical outcomes, according to a new study of nearly 27,000 adults.
FDA approves labeling changes for fenofibrates due to lack of cardiovascular benefits
The FDA listened to physician feedback and updated its labeling requirements for fenofibrates. These drugs have not been linked to any significant cardiovascular benefits, and clinicians should act accordingly.
FDA approves subcutaneous diuretic treatment for heart failure-related edema
The newly approved drug-device combination helps patients manage their own treatment from the comfort of home.

FDA approves oral semaglutide for reducing cardiovascular risks in adults with type 2 diabetes

Rybelsus from Novo Nordisk is officially the first oral GLP-1 drug approved for this indication. The FDA's decision was based on the SOUL trial, which included data from more than 9,000 patients with type 2 diabetes.

Hypertrophic Cardiomyopathy Association supports study of potential treatment for nonbstructive HCM

No medications are currently approved for the treatment of nonobstructive hypertrophic cardiomyopathy. Could a new drug from Imbria Pharmaceuticals be the first?

SGLT2 inhibitors after TAVR may boost survival, limit bioprosthetic valve dysfunction

Prescribing these drugs to TAVR patients could improve certain clinical outcomes, according to a new study of nearly 27,000 adults.

doctor patient elderly check up hospital

FDA approves labeling changes for fenofibrates due to lack of cardiovascular benefits

The FDA listened to physician feedback and updated its labeling requirements for fenofibrates. These drugs have not been linked to any significant cardiovascular benefits, and clinicians should act accordingly.

FDA approves subcutaneous diuretic treatment for heart failure-related edema

The newly approved drug-device combination helps patients manage their own treatment from the comfort of home.

obesity semaglutide tirzepatide GLP-1 drugs weight loss

Obesity drugs under review: Semaglutide, tirzepatide, naltrexone/bupropion all boost heart health

The popularity of various obesity management medications has increased significantly in recent years. According to a new analysis of more than 60,000 patients, some of these drugs are associated with more cardiovascular benefits than others.

DAPT during valve-in-valve TAVR may reduce stroke risk—more data still required

New research suggests there may be a cardiovascular benefit to considering dual antiplatelet therapy for valve-in-valve TAVR patients.

The universal screening of children for familial hypercholesterolemia can save lives

If familial hypercholesterolemia is not detected and treated early, it can lead to premature heart attacks and heart disease in young patients.